Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
Diagnosis & Disease Information
Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
How Prior Alkylator Exposure Impacts the Efficacy of Melflufen in Multiple Myeloma
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Gilteritinib Shows Efficacy in Patients With Acute Myeloid Leukemia With Prior Tyrosine Kinase Inhibitor Therapy
Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.
Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Comorbidities Don’t Hinder Dasatinib’s Activity in Chronic Phase Chronic Myeloid Leukemia
Dasatinib produced responses regardless of comorbidity burden.
Brentuximab Vedotin Plus CHP Provides Lasting Benefit in Peripheral T-Cell Lymphoma
The combination continued to best CHOP at 5 years.
Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple Myeloma
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Algorithmic Approach to Identify Patients With Germline Predisposition Syndromes, Including Those With Hematologic Malignancies
Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.
Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
- Loading...
Loading...
Next post in SOHO 2021
Loading... 
Loading...